$CTMX
CytomX Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023019654 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $24.72M $23.50M
YoY Change 36.11% 37.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.401M $7.977M
YoY Change -37.0% -24.34%
% of Gross Profit
Research & Development $20.67M $21.18M
YoY Change -33.66% -30.71%
% of Gross Profit
Depreciation & Amortization $610.0K $595.0K
YoY Change 0.0% -1.16%
% of Gross Profit
Operating Expenses $28.07M $29.15M
YoY Change -34.57% -29.07%
Operating Profit -$3.348M -$5.653M
YoY Change -86.47% -76.41%
Interest Expense $2.308M $2.327M
YoY Change 780.92% 3322.06%
% of Operating Profit
Other Income/Expense, Net -$47.00K $15.00K
YoY Change -115.88% 15.38%
Pretax Income -$1.087M -$3.311M
YoY Change -95.51% -86.14%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.087M -$3.311M
YoY Change -95.51% -86.14%
Net Earnings / Revenue -4.4% -14.09%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.02 -$0.05
COMMON SHARES
Basic Shares Outstanding 66.34M 66.23M
Diluted Shares Outstanding 66.54M 66.25M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $180.9M $204.5M
YoY Change -20.73% -22.1%
Cash & Equivalents $57.54M $56.36M
Short-Term Investments $123.3M $148.1M
Other Short-Term Assets $5.040M $6.685M
YoY Change 40.35% 36.48%
Inventory
Prepaid Expenses
Receivables $1.903M $1.090M
Other Receivables $0.00 $0.00
Total Short-Term Assets $187.8M $212.3M
YoY Change -19.32% -20.92%
LONG-TERM ASSETS
Property, Plant & Equipment $4.499M $4.573M
YoY Change -23.94% -24.95%
Goodwill $949.0K $949.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $91.00K $27.00K
YoY Change -89.83% -97.01%
Total Long-Term Assets $21.38M $22.35M
YoY Change -21.72% -21.24%
TOTAL ASSETS
Total Short-Term Assets $187.8M $212.3M
Total Long-Term Assets $21.38M $22.35M
Total Assets $209.2M $234.6M
YoY Change -19.57% -20.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.029M $2.203M
YoY Change -46.41% 28.01%
Accrued Expenses $20.07M $22.28M
YoY Change -36.76% -28.22%
Deferred Revenue $120.3M $126.8M
YoY Change 82.83% 81.09%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $141.4M $151.3M
YoY Change 42.17% 47.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $216.0K $170.0M
YoY Change -99.81% 35.07%
Total Long-Term Liabilities $216.0K $170.0M
YoY Change -99.81% 35.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $141.4M $151.3M
Total Long-Term Liabilities $216.0K $170.0M
Total Liabilities $294.2M $321.3M
YoY Change 39.19% 40.52%
SHAREHOLDERS EQUITY
Retained Earnings -$727.3M -$726.2M
YoY Change 25.01% 30.23%
Common Stock $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$85.03M -$86.64M
YoY Change
Total Liabilities & Shareholders Equity $209.2M $234.6M
YoY Change -19.57% -20.95%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.087M -$3.311M
YoY Change -95.51% -86.14%
Depreciation, Depletion And Amortization $610.0K $595.0K
YoY Change 0.0% -1.16%
Cash From Operating Activities -$25.18M $9.349M
YoY Change -26.46% -122.63%
INVESTING ACTIVITIES
Capital Expenditures $517.0K $48.00K
YoY Change -225.49% -93.48%
Acquisitions
YoY Change
Other Investing Activities $26.56M -$146.6M
YoY Change
Cash From Investing Activities $26.04M -$146.6M
YoY Change -6420.39% 19824.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 317.0K 0.000
YoY Change -29.71% -100.0%
NET CHANGE
Cash From Operating Activities -25.18M 9.349M
Cash From Investing Activities 26.04M -146.6M
Cash From Financing Activities 317.0K 0.000
Net Change In Cash 1.179M -137.3M
YoY Change -103.45% 226.56%
FREE CASH FLOW
Cash From Operating Activities -$25.18M $9.349M
Capital Expenditures $517.0K $48.00K
Free Cash Flow -$25.70M $9.301M
YoY Change -24.04% -122.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001501989
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37587
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
515-3185
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
CTMX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66338938
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56357000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193650000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
148145000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1090000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35986000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6685000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7466000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
212277000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
237102000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4573000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5072000
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
839000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
875000
CY2023Q1 us-gaap Goodwill
Goodwill
949000
CY2022Q4 us-gaap Goodwill
Goodwill
949000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15048000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15949000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2023Q1 us-gaap Assets
Assets
234630000
CY2022Q4 us-gaap Assets
Assets
260891000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2203000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2809000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22275000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28532000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
126784000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
121267000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
151262000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
152608000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
157133000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
180059000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12872000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13975000
CY2023Q1 us-gaap Liabilities
Liabilities
321267000
CY2022Q4 us-gaap Liabilities
Liabilities
346642000
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
639526000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
637117000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-726190000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-722879000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-86637000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-85751000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234630000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260891000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23499000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9040000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21175000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30559000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7977000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10543000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
29152000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
41102000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5653000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32062000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2327000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
68000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3311000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31981000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
16000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-677000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3295000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32658000
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.05
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.49
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.49
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66248992
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66248992
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65393691
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65393691
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-85751000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2409000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
16000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3311000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-86637000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-459000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3370000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-677000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31981000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-29740000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3311000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-31981000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
36000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37000
CY2023Q1 ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
559000
CY2022Q1 ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
565000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1535000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
17000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2409000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3370000
CY2023Q1 ctmx Noncash Lease Expense
NoncashLeaseExpense
-901000
CY2022Q1 ctmx Noncash Lease Expense
NoncashLeaseExpense
-826000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34896000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
232000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-781000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
613000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-618000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1060000
CY2023Q1 ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-7360000
CY2022Q1 ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-4182000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-17409000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8025000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9349000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41313000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
736000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
146594000
CY2022Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146642000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-736000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-137293000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-42042000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194567000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57274000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
164405000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193650000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163488000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="notes_to_condensed_financial_statements" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Descriptio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n of the Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56357000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57274000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194567000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
164405000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15525577
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14545414
CY2023Q1 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
205830000
CY2023Q1 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
26000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
205856000
CY2022Q4 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
95564000
CY2022Q4 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
95574000
CY2023Q1 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
12500000
CY2022Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
13089000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4372000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8060000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
757000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1413000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4204000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4082000
CY2023Q1 ctmx Restructuring Expenses
RestructuringExpenses
83000
CY2022Q4 ctmx Restructuring Expenses
RestructuringExpenses
1627000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
359000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
261000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22275000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28532000
CY2023Q1 us-gaap Revenues
Revenues
23499000
CY2022Q1 us-gaap Revenues
Revenues
9040000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
301326000
CY2023Q1 ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
869000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
18278000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
283917000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
284760000
CY2022Q1 ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
1058000
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
9084000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
276734000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
283900000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13289838
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.67
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1151023
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.59
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
307176
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.89
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14133685
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.30
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1676000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
1425000
CY2023Q1 ctmx Change Of Estimates
ChangeOfEstimates
-168000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
83000
CY2023Q1 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Remainder Of Fiscal Year
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsRemainderOfFiscalYear
974000
CY2023Q1 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Next Twelve Months
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInNextTwelveMonths
1333000
CY2023Q1 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Year Two
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInYearTwo
1379000
CY2023Q1 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Year Three
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInYearThree
1067000
CY2023Q1 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
4753000

Files In Submission

Name View Source Status
ctmx-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ctmx-20230331_pre.xml Edgar Link unprocessable
0000950170-23-019654-index-headers.html Edgar Link pending
0000950170-23-019654-index.html Edgar Link pending
0000950170-23-019654.txt Edgar Link pending
0000950170-23-019654-xbrl.zip Edgar Link pending
ctmx-20230331.htm Edgar Link pending
ctmx-20230331.xsd Edgar Link pending
ctmx-20230331_cal.xml Edgar Link unprocessable
ctmx-ex10_1.htm Edgar Link pending
ctmx-ex31_1.htm Edgar Link pending
ctmx-ex31_2.htm Edgar Link pending
ctmx-ex32_1.htm Edgar Link pending
ctmx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img13886920_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
ctmx-20230331_lab.xml Edgar Link unprocessable
ctmx-20230331_htm.xml Edgar Link completed
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending